ImprimisRx (Harrow subsidiary) appoints Frank Mullery as CEO; prior CEO John Saharek transitions out

HARROW, INC.

John Saharek ceased as President/CEO of ImprimisRx effective Oct 6, 2025; transitions to non-officer role with no new compensation.
Frank Mullery appointed CEO of ImprimisRx; previously President of Sintetica US and led Mylan Institutional to >$1B revenue.
Bridseida Cruz appointed Head of Quality; over 25 years experience in FDA remediation and operational improvement.
No compensatory arrangements entered with Saharek in connection with transition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.